Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
42 Leser
Artikel bewerten:
(0)

Global Transdermal Patch Market Outlook 2022 - Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase

DUBLIN, August 8, 2017 /PRNewswire/ --

The "Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

Transdermal patches are widely accepted among physicians and patients due to their non-invasive, pain free and easy administration. In recent years, the growth of transdermal patch market has increased and expected to increase significantly in coming years. Higher investments in research and development could be attributed to the success of transdermal patch market. Number of disease indication treated by them is increasing steadily leading to higher market penetration. Every year various transdermal patches are introduced in globally leading to increased market size.

Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician.

Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.

Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment.

Companies Mentioned

  • 3M Pharmaceuticals
  • ANI Pharmaceuticals
  • Acrux
  • Agile Therapeutics
  • Allergan
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Chase Pharmaceuticals
  • Corium International
  • DURECT Corporation
  • Endo Pharmaceuticals
  • Fempharm
  • Hisamitsu Pharmaceutical
  • Immune Pharmaceuticals
  • Imprimis Pharmaceuticals
  • Ipsen Bioscience
  • Johnson & Johnson
  • LaSalle Laboratories
  • Lavipharm-increase
  • MINRAD International
  • NeurogesX
  • Novartis
  • Noven Pharmaceuticals
  • NuPathe
  • Nuvo Research
  • Pain Therapeutics
  • (10+ Others)

Key Topics Covered:

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. Global Transdermal Patch Market Outlook

7. Global Transdermal Patch Clinical Pipeline Overview

8. Global Transdermal Patch Market Dynamics

9. Global Transdermal Patch Market Future Prospects

10. Global Transdermal Patch Clinical Insight

11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase

12. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/2scxsn/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.